Clinical Trial Update: Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical study evaluating an EBV-LMP1 targeted DNAzyme for nasopharyngeal carcinoma has completed (Phase 1 and Phase 2) under Xiangya Hospital of Ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• EBV-LMP1 targeted DNAzyme

Snippet

Sponsor: Xiangya Hospital of Central South University | Conditions: Nasopharyngeal Carcinoma | Phase 1, Phase 2 | Status: COMPLETED